A comprehensive investigation of the photophysics of a cofacially oriented bis-coumarin based on naphthalene, i.e., Cou-Nap, designed and synthesized to examine the influence of π-electronic communication between the two fluorophores, reveals exceptional excited-state properties. While the anticipated [2 + 2] photocycloaddition is not observed despite the fact that the two reactive coumarin units are at a distance of 3.8 Å, the fluorescence quantum yields and singlet lifetimes in different solvents are found to be remarkably higher when compared to those of the parent coumarin and a mono-coumarin model system, i.e., Cou-Dur. In addition to large solvent-induced Stokes shifts, Cou-Nap displays intriguing temperature-dependent emission in a nonpolar solvent such as cyclohexane. The observed photophysical properties are reconciled based on the so-called 'phane effect' that is operative in cyclophanes. In the latter, an effective π-π interaction between the aromatic rings modifies the attributes of the chromophore in such a manner that the observed properties cannot be associated with the individual aromatic rings. The temperature-dependent emission is proposed to arise as a consequence of thermally activated ISC from the singlet-excited state to one of the higher energy triplet states. The results constitute, for the first time, the demonstration of modification of the excited-state properties of a fluorophore in a non-cyclophane system by 'phane effect'.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1039/c6cp07720j | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic in an in vitro and in vivo model of CDKL5 deficiency disorder.
J Neurodev Disord
November 2024
Department of Biomedical and Neuromotor Science, University of Bologna, Piazza Di Porta San Donato 2, 40126, Bologna, Italy.
Background: Mutations in the X-linked CDKL5 gene underlie a severe epileptic encephalopathy, CDKL5 deficiency disorder (CDD), characterized by gross motor impairment, autistic features and intellectual disability. Absence of Cdkl5 negatively impacts neuronal proliferation, survival, and maturation in in vitro and in vivo models, resulting in behavioral deficits in the Cdkl5 KO mouse. While there is no targeted therapy for CDD, several studies showed that treatments enabling an increase in brain BDNF levels give rise to structural and behavioral improvements in Cdkl5 KO mice.
View Article and Find Full Text PDFA Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
Clin Cancer Res
October 2024
Sarah Cannon Research Institute, Nashville, Tennessee.
Article Synopsis
- The study explores the use of a CD73 inhibitor (oleclumab) combined with durvalumab and chemotherapy in treating pancreatic ductal adenocarcinoma (PDAC), targeting immune surveillance evasion.
- Conducted across multiple centers, the trial included patients with metastatic PDAC in two cohorts, assessing safety and response rates with various treatment combinations for the chemotherapy regimens.
- While safety results were acceptable, the trial did not achieve its main goal of demonstrating significant treatment efficacy, although some patients with high CD73 levels showed improved outcomes.
Calls to action on lung cancer management and research.
Oncologist
December 2024
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.
Lung cancer, the leading cause of cancer-related deaths globally, remains a pressing health issue despite significant medical advances. The New York Lung Cancer Foundation brought together experts from academia, the pharmaceutical and biotech industries as well as organizational leaders and patient advocates, to thoroughly examine the current state of lung cancer diagnosis, treatment, and research. The goal was to identify areas where our understanding is incomplete and to develop collaborative public health and scientific strategies to generate better patient outcomes, as highlighted in our "Calls to Action.
View Article and Find Full Text PDFArticle Synopsis
- The RESILIENT trial compared the effectiveness of liposomal irinotecan and topotecan as second-line treatments for small cell lung cancer (SCLC) after initial chemotherapy.
- No significant difference in overall survival (OS) was observed, with liposomal irinotecan showing a median OS of 7.9 months and topotecan at 8.3 months.
- Liposomal irinotecan had a higher objective response rate (ORR) of 44.1% compared to 21.6% for topotecan, but both treatments had similar safety profiles with grade ≥3 adverse events.
Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors.
Cancer Med
February 2024
Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Article Synopsis
- Sapanisertib, a dual mTORC1/2 inhibitor, was combined with ziv-aflibercept, an anti-VEGF treatment, in a Phase 1 study to assess its safety and effectiveness in patients with advanced solid tumors.
- Fifty-five heavily pre-treated patients participated, with the treatment showing a maximum tolerated dose of sapanisertib and ziv-aflibercept resulting in notable side effects like hypertension and fatigue but no severe (grade 5) complications.
- The combination therapy showed promising anti-tumor activity, with 74% of patients achieving stable disease and an overall disease control rate of 78%.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!